Ignite Creation Date:
2024-05-06 @ 6:58 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05848219
Status:
TERMINATED
Last Update Posted:
2023-05-08
First Post:
2023-04-27
Brief Title:
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib Trametinib and Encorafenib Binimetinib
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib Trametinib and Encorafenib Binimetinib
Status:
TERMINATED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Company decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a retrospective cohort study using the MarketScan health care administrative claim databases Truven Health Analytics MarketScan Commercial Claims and Encounters MarketScan Medicare Supplement and Coordination of Benefit We conducted this analysis using the most recent available data from the MarketScan database at the time of analysis which was 01 June 2018 to 31 December 2020 We initiated this analysis from 01 June 2018 as encorafenib binimetinib encobini was approved for patients with unresectable or metastatic melanoma with BRAF mutation at this time
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None